AGREEMENT CONCERNING GLUCOKINASE ACTIVATOR PROJECT BY AND BETWEEN NOVO NORDISK A/S AND TRANSTECH PHARMA, INC. DATED AS OF FEBRUARY 20, 2007Agreement Concerning Glucokinase Activator Project • August 4th, 2021 • vTv Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 4th, 2021 Company Industry JurisdictionTHIS AGREEMENT CONCERNING GLUCOKINASE ACTIVATOR PROJECT (this “Agreement”) is entered into this 20th day of February, 2007 (the “Effective Date”), by and between Novo Nordisk A/S, a corporation organized under the laws of Denmark, having a business address at Novo Allé, DK-2880 Bagsvaerd, Denmark (“Novo”), and TransTech Pharma, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265, USA (“TransTech”).
AGREEMENT CONCERNING GLUCOKINASE ACTIVATOR PROJECT BY AND BETWEEN NOVO NORDISK A/S AND TRANSTECH PHARMA, INC. DATED AS OF FEBRUARY 20, 2007Agreement Concerning Glucokinase Activator Project • July 2nd, 2015 • vTv Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 2nd, 2015 Company Industry JurisdictionTHIS AGREEMENT CONCERNING GLUCOKINASE ACTIVATOR PROJECT (this “Agreement”) is entered into this 20th day of February, 2007 (the “Effective Date”), by and between Novo Nordisk A/S, a corporation organized under the laws of Denmark, having a business address at Novo Allé, DK-2880 Bagsvaerd, Denmark (“Novo”), and TransTech Pharma, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265, USA (“TransTech”).
AGREEMENT CONCERNING GLUCOKINASE ACTIVATOR PROJECT BY AND BETWEEN NOVO NORDISK A/S AND TRANSTECH PHARMA, INC. DATED AS OF FEBRUARY 20, 2007Agreement Concerning Glucokinase Activator Project • June 19th, 2015 • vTv Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 19th, 2015 Company Industry JurisdictionTHIS AGREEMENT CONCERNING GLUCOKINASE ACTIVATOR PROJECT (this “Agreement”) is entered into this 20th day of February, 2007 (the “Effective Date”), by and between Novo Nordisk A/S, a corporation organized under the laws of Denmark, having a business address at Novo Allé, DK-2880 Bagsvaerd, Denmark (“Novo”), and TransTech Pharma, Inc., a corporation organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265, USA (“TransTech”).